About
Development of antibodies from phage display discovery
Areas of Focus
Categories
Contract ResearchContract ResearchContract ResearchAntibodyAustralia
Team (3)
Clinical Trials (7)
View allTotal Trials
7
As Lead Sponsor
7
As Collaborator
0
Total Enrollment
636
By Phase
PHASE1/PHASE2: 3NA: 1PHASE4: 1PHASE2/PHASE3: 1
By Status
UNKNOWN: 3COMPLETED: 3ENROLLING_BY_INVITATION: 1
Clinical Trials Pipeline7 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT05270954Lead Sponsor
Safety, Tolerability and Immunogenicity of Recombinant COVID-19 Vaccine Betuvax-CoV-2
PHASE1/PHASE2Unknown
116 participants
Started: Oct 14, 2021 · Completed: Jul 24, 2022
NCT04824040Lead Sponsor
Clinical, Immunological, Morphological and Genetic Characteristics of Patients With Dysferlinopathy (LGMD R2) in the RF
N/AEnrolling by invitation
100 participants
Started: Jan 15, 2020 · Completed: Jul 31, 2027
NCT02538705Lead Sponsor
Safety and Efficacy Study of Neovasculgen (Pl-VEGF165) Gene Therapy in Patients With Diabetic Foot
NACompleted
35 participants
Started: Aug 31, 2015 · Completed: Jan 1, 2016
NCT02352649Lead Sponsor
Safety and Efficacy Study of Neovasculgen (Pl-VEGF165) Gene Therapy in Patients With Peripheral Nerve Injury
PHASE1/PHASE2Unknown
45 participants
Started: Apr 30, 2015 · Completed: Sep 30, 2017
NCT02356809Lead Sponsor
Safety and Efficacy Study of Gene Therapy Drug (Neovasculgen) to Treat Secondary Raynaud's Phenomenon
PHASE1/PHASE2Unknown
30 participants
Started: Mar 31, 2015 · Completed: Aug 31, 2015
Locations (1)
Headquarters
Brisbane, Australia
Map
Loading map...